Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Elanix Biotechnologies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Elanix Biotechnologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elanix Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Elanix Biotechnologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Elanix Biotechnologies's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Elanix Biotechnologies's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Elanix Biotechnologies is high growth as no earnings estimate data is available.
Unable to determine if Elanix Biotechnologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Elanix Biotechnologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Elanix Biotechnologies's finances.
The net worth of a company is the difference between its assets and liabilities.
Elanix Biotechnologies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Elanix Biotechnologies's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Elanix Biotechnologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Elanix Biotechnologies has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
How Financially Strong Is Elanix Biotechnologies AG (FRA:ELN)?
Elanix Biotechnologies AG (FRA:ELN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Does ELN's growth rate justify its decision for financial flexibility over lower cost of capital. … But the downside of having debt in a company’s balance sheet is the debtholder’s higher claim on its assets in the case of liquidation, as well as stricter capital management requirements.
Do Institutions Own Elanix Biotechnologies AG (FRA:ELN) Shares?
The big shareholder groups in Elanix Biotechnologies AG (FRA:ELN) have power over the company. … Elanix Biotechnologies is a smaller company with a market capitalization of €15m, so it may still be flying under the radar of many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.
Are Elanix Biotechnologies AG's (FRA:ELN) Interest Costs Too High?
Elanix Biotechnologies AG (FRA:ELN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is financial flexibility worth the lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital
Is Elanix Biotechnologies AG (FRA:ELN) A Financially Sound Company?
The direct benefit for Elanix Biotechnologies AG (FRA:ELN), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is ELN right in choosing financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.
What Does Elanix Biotechnologies AG's (FRA:ELN) Ownership Structure Look Like?
In this article, I'm going to take a look at Elanix Biotechnologies AG’s (DB:ELN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Therefore, it is beneficial for us to examine ELN's ownership structure in more detail. … View our latest analysis for Elanix Biotechnologies DB:ELN Ownership_summary Apr 9th 18 Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital.
How Does Investing In Elanix Biotechnologies AG (FRA:ELN) Impact Your Portfolio?
A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, ELN appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … As a result, the company may be less volatile relative to broad market movements, compared to a company of similar size but higher proportion of fixed assets.
Does Elanix Biotechnologies AG's (FRA:ELN) Earnings Growth Make It An Outperformer?
Check out our latest analysis for Elanix Biotechnologies How Did ELN's Recent Performance Stack Up Against Its Past? … For Elanix Biotechnologies, its most recent earnings (trailing twelve month) is -€2.78M, which, relative to the previous year's figure, has become less negative. … This shows that, Elanix Biotechnologies has historically performed better than recently, though it seems like earnings are now heading back towards a more favorable position once more.
Elanix Biotechnologies AG develops and commercializes products for acute wound care, and dermatological and gynecological applications. The company develops and markets progenitor cell-based products that are used to regenerate tissue and promote healing in the treatment of burns, and gynecological and dermatological conditions. Its products include GYNrepair, a cream for genital external mucosa; and SKINrepair, a cream for skin that protects against external aggressions. The company is also developing FirstCover, an acute wound care tissue engineering product that is used to provide protection and healing for burns, and trauma and plastic surgery. In addition, it offers cell technology services. Elanix Biotechnologies AG has a co-development agreement with Dermacon GmbH to develop medical devices for its wound care franchise. The company was formerly known as Porta Systems AG and changed its name to Elanix Biotechnologies AG in December 2015. Elanix Biotechnologies AG is based in Potsdam, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.